{"id":"W4408246183","doi":"10.1007/s10637-025-01518-7","title":"First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma","year":2025,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Neutropenia; Medicine; Cmax; Pharmacodynamics; Pharmacokinetics; Adverse effect; Maculopapular rash; Rash; Internal medicine; Gastroenterology; Area under the curve; Lymphoma; Pharmacology; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001183067,0.001579078,0.002018984,0.0005319752,0.0005131887,0.001196197,0.0008277099,0.00097978,0.002779989],"category_scores_gemma":[0.0004866073,0.0006293653,0.001039346,0.0004262339,0.001140333,0.0008766585,0.0003416776,0.003391988,0.0008207021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00143285,"about_ca_system_score_gemma":0.001484033,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001912535,"about_ca_topic_score_gemma":0.004564729,"domain_scores_codex":[0.9996263,0.0001386667,0.00001163272,0.00006354846,0.00003375548,0.0001261091],"domain_scores_gemma":[0.9996409,0.00004934895,0.00003977108,0.00003339868,0.00001763394,0.0002188478],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4712683,0.2055162,0.008011415,0.0009241317,0.001741979,0.000614096,0.0007726529,0.01001687,0.1353933,0.0008017847,0.009838243,0.1551011],"study_design_scores_gemma":[0.3161099,0.6476474,0.01329973,0.00002718646,0.0005381285,0.0003914224,0.0001700572,0.003273062,0.01318677,0.0004053285,0.00489739,0.00005362921],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932365,0.001526191,0.0006398337,0.0003884833,0.000112573,0.001254653,0.0008004523,0.0001280513,0.001913313],"genre_scores_gemma":[0.9928319,0.001051271,0.0009830412,0.0004862923,0.00007719045,0.0007904987,0.001117959,0.00003914333,0.002622644],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002779989,"threshold_uncertainty_score":0.01039612,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01274599359576806,"score_gpt":0.3056246908301644,"score_spread":0.2928786972343963,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}